This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jan 31:4:160133.
doi: 10.1038/sdata.2016.133.

A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection

Affiliations
Meta-Analysis

A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection

Hilary Bower et al. Sci Data. .

Abstract

Asymptomatic ebolavirus infection could greatly influence transmission dynamics, but there is little consensus on how frequently it occurs or even if it exists. This paper summarises the available evidence on seroprevalence of Ebola, Sudan and Bundibugyo virus IgG in people without known ebolavirus disease. Through systematic review, we identified 51 studies with seroprevalence results in sera collected from 1961 to 2016. We tabulated findings by study population, contact, assay, antigen and positivity threshold used, and present seroprevalence point estimates and 95% confidence intervals. We classified sampled populations in three groups: those with household or known case-contact; those living in outbreak or epidemic areas but without reported case-contact; and those living in areas with no recorded cases of ebolavirus disease. We performed meta-analysis only in the known case-contact group since this is the only group with comparable exposures between studies. Eight contact studies fitted our inclusion criteria, giving an overall estimate of seroprevalence in contacts with no reported symptoms of 3.3% (95% CI 2.4-4.4, P<0.001), but with substantial heterogeneity.

PubMed Disclaimer

Conflict of interest statement

H.B. and J.R.G. declare they have no competing financial interests nor conflicts of interest. Both authors have had had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Figures

Figure 1
Figure 1. Forest plot and meta-analysis of seroprevalence of ebolavirus IgG among contacts of EVD cases reported to be asymptomatic during the outbreak period.
Further details of each included study are given in Table 1. Legend: Ref: reference number; IFA: Immunofluorescence Assay; ELISA: Enzyme-linked immunosorbent assay; ES: Estimated proportion; N, NW: North, Northwestern; SL: Sierra Leone; W. Area: Western Area Province. Note: Zaire now Democratic Republic of Congo; Rhodesia now Zimbabwe.
Figure 2
Figure 2. Forest plot of seroprevalence of ebolavirus IgG in individuals reported to be asymptomatic during the outbreak period, recruited in areas with known EVD cases, excluding direct contacts of EVD cases.
Further details of each included study are given in Table 1. Legend: Ref: reference number; ES: Estimated proportion; IFA: Immunofluorescence Assay ELISA: Enzyme-linked immunosorbent assay; DRC: Democratic Republic of Congo; N, NE: North, Northeastern.
Figure 3
Figure 3. Forest plot of seroprevalence of ebolavirus IgG in general populations living in areas without reported EVD cases.
Further details of each included study are given in Table 1. Legend: Ref: reference number; IFA: Immunofluorescence Assay; ELISA: Enzyme-linked immunosorbent assay; ES: Estimated proportion; IFA: Immunofluorescence Assay; ELISA: Enzyme-linked immunosorbent assay; DRC: Democratic Republic of Congo; RoC: Republic of Congo; CAR: Central African Republic; N, NW: North, Northwestern. Note: Zaire now Democratic Republic of Congo; Rhodesia now Zimbabwe.

References

Data Citations

    1. Bower H, Glynn J. R. 2016. Dryad Digital Repository. http://dx.doi.org/10.5061/dryad.gn95r - DOI

References

    1. Tignor G. H., Casals J. & Shope R. E. The yellow fever epidemic in Ethiopia, 1961-1962: retrospective serological evidence for concomitant Ebola or Ebola-like virus infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 162 (1993). - PubMed
    1. van der Groen G. & Pattyn S. R. Measurement of Antibodies to Ebola Virus in Human-Sera from Nw-Zaire. Annales de la Societe belge de medecine tropicale 59, 87–92 (1979). - PubMed
    1. Neppert J., Gohring S., Schneider W. & Wernet P. No Evidence of Lav Infection in the Republic-of-Liberia, West-Africa, in the Year 1973. Blut 53, 115–117 (1986). - PubMed
    1. van der Groen G., Johnson K., Webb F., Wulff H, Lange J. in Ebola Virus Haemorrhagic Fever (ed. Pattyn S. R. 141–142 (Elsevier/North-Holland Biomedical Press, 1978).
    1. The International Commission. Ebola Haemorrhagic Fever in Zaire. Bulletin WHO (1976).

Publication types

Cite

AltStyle によって変換されたページ (->オリジナル) /